BCL2 (B-cell CLL/lymphoma 2)

Molecular docking confirmed the stable binding of compound 1 to B-cell lymphoma 2 (BCL-2) and mitogen-activated protein kinase kinase 1 (MAP2K1) with binding free energies of -8.9 kcal mol-1 and -9.6 kcal mol-1, respectively. Overall, these results elucidate the dual antitumor mechanisms of compound 1, demonstrating its potential as a lead candidate for treating leukaemia and cervical cancer.

P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

P1, N=42, Not yet recruiting, University of Pennsylvania | Trial completion date: Apr 2043 --> Jul 2051 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2043 --> Jul 2051

Moreover, achieving PB WT1 mRNA negativity-regardless of whether this occurred early or later in the therapy།was consistently associated with superior OS and PFS. These findings suggest that PB WT1 mRNA is a sensitive and reliable biomarker for predicting treatment response and long-term outcomes in patients with AML receiving VEN/AZA.

Notably, the same portion forms an α-helix when binding to B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra-large (Bcl-xL), suggesting that HBx uses different conformations to interact with distinct targets. This structural plasticity may underlie the multifunctional roles of HBx.

Troxerutin (TXR) is a bioflavonoid with demonstrated cardioprotective properties in various cardiac injury models, including cardioprotective effects in doxorubicin-induced myocardial injury, as well as diabetic myocardiopathy. Importantly, TXR did not abrogate the anticancer activity of PXT in cultured human MDA-MB cells. In conclusion, TXR hindered the cardiotoxicity of PXT and showed cardioprotective effects via its inhibitory actions on ER stress, ferroptosis, oxidative stress, and apoptosis.

Among them, rhein exhibited significant anti-proliferative activity, superior to carboplatin, with an IC₅₀ value of 72.4 ± 3.7 μM against CAL-27 cells...Moreover, rhein not only activates the mitochondrial-mediated apoptosis signaling pathway (Bax/Bcl-2/cytochrome C/cleaved caspase-3) but also highly activates the expression level of the DNA damage protein γ-H2AX. This study provides new insights into the development of natural anthraquinone compounds as promising candidates for oral cancer therapies.

Furthermore, the 50 µg/mL OMV +250 µg/mL V. myrtillus treatment group showed approximately a 0.75-fold increase in PTEN and BAX gene expression, accompanied by a correlated decrease in AKT and BCL-2 gene expression, compared to the control group. These results suggest that OMV-mediated delivery of V. myrtillus represents a promising synergistic therapeutic approach for treatment-resistant pancreatic cancer.

In conclusion, the present study demonstrated the pro‑apoptotic effect of CEP in TNBC cells and identified lysosomal enzymes as the direct target for its mechanism of action. These findings provided a foundation for further investigation of the pharmacological mechanisms of CEP.

CSB-NC showed a synergistic protective effect against cardiovascular toxicity induced by Dox when combined with saponin, chitosan, and bentonite.

In addition, silencing of CREB3L4 promoted apoptosis and inhibited cell proliferation, which was also associated with decreased BAG3 expression. Taken together, these findings indicate that depletion of CREB3L4 suppressed autophagy and reduced cisplatin resistance in GC cells by downregulating BAG3.

Furthermore, GET3 deficiency promoted MCL1 downregulation and accelerated apoptosis during prolonged mitotic arrest. These findings underscore the importance of the GET pathway in regulating apoptosis and MCL1's tail-anchoring.